Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Nabs $7.5 Million in Debt-Financing

NEW YORK, July 10 - Paradigm Genetics will pocket $7.5 million as part of a  debt-financing deal with Silicon Valley Bank of Santa Clara, Calif., Paradigm said today.

 

Paradigm said the financing includes a $5 million, four-year secured-term loan and a $2.5 million revolving line of credit. The firm added that the loan is at a "significantly lower [interest] rate" than its existing loan.

 

Paradigm, based in Research Triangle Park, NC, will use around $3 million of the term loan to pay off its current equipment financing loan with Transamerica Technology Finance, which was to mature in June 2004. The company said it will use the balance of the cash for "general corporate purposes."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.